

Development of a new therapeutic agent for bone metastasis cancer through the development of anti-***** humanized antibody

Cellus, Inc



ONCOLOGY	Hit
Product Type	***** humanized antibody (Biopharmaceutical)
Indication	Bone metastasis from solid cancer, breast cancer and bone metastasis from prostate cancer
Target	***** protein abundantly present in the bone metastasis microenvironment
MoA(Mechanism of Action)	<p>Inhibition of ***** protein activity</p> <ul style="list-style-type: none"> - Blocks the recruitment of progenitor cells in the bone microenvironment that creates a vicious cycle of cancer cells-osteocytes-immune cells - Due to the decrease in progenitor cell recruitment, the number of osteoblasts decreases, suppressing the activity of osteoclasts and suppressing the secretion of cancer growth factors.
Competitiveness	<ul style="list-style-type: none"> - Novelty of anti-***** target (First in class) - Existing drug resistance overcoming mechanism target - Targets with high tumor specificity - Targets that can cover both primary and metastatic cancer - Potential as a rare-intractable treatment
Development Stage	Hit
Route of Administration	Subcutaneous injection / 25-150 mg, once / 3-4 weeks